Alpha-fetoprotein, stem cells and cancer: How study of the production of alpha-fetoprotein during chemical hepatocarcinogenesis led to reaffirmation of the stem cell theory of cancer

Tumor Biology

Volumn 29, Issue 3, 2008, Pages 161-180

  Sell, Stewart ^a  

^a ORDWAY RESEARCH INSTITUTE   (United States)

Author keywords

Alpha fetoprotein; Cancer; Stem cells; Fetoprotein

Indexed keywords

ALPHA FETOPROTEIN; DIETHYLNITROSAMINE; N (2 FLUORENYL)ACETAMIDE;

BILE DUCT CARCINOMA; BONE MARROW CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STEM CELL; CANCER THERAPY; CELL MATURATION; CELL POPULATION; CELL PROLIFERATION; CELL RENEWAL; EMBRYO CELL; EMBRYO DEVELOPMENT; HEPATOBLASTOMA; HUMAN; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER DEVELOPMENT; LIVER INJURY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN SYNTHESIS; RADIOIMMUNOASSAY; REVIEW; TERATOCARCINOMA; VITAMIN DEFICIENCY;

EID: 46449130337     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000143402     Document Type: Review

References (188)

1. Bergstrand CF, Czar B: Demonstration of a new protein fraction in serum from the human fetus. Scand J Clin Lab Invest 1956;8:174.
2. De Muralt G, Roulet DLA: Etude immunologique des proteines seriques foetales humaines. Helv Paediat Acta 1961;16:517-533.
3. Masopust J: Development of serum protein spectrum during childhood. Rev Czech Med 1962;8:214-225.
4. Abelev GI, Perova SD, Khramkova NI, Postnikova AS, Irlin IS: Production of embryonal α-globulin by transplantable mouse hematomas. Transplantation 1963;1:174-180.
5. Tatarinov YS: Presence of embryonal α-globulin in the serum of patients with primary hepatocellular carcinomas. Vopr Med Khim 1964;10:90-91.
6. Gold P, Freedman SL: Specific carcinoembryonic antigens of the human digestive system. J Exp Med 1965;122:467-481.
7. Fishman WH, Sell S: Onco-Developmental Gene Expression. New York, Academic Press, 1976, pp 1-788.
8. Pierce GB, Shikes R, Fink LM: Cancer: A Problem of Developmental Biology. Engelwood Cliffs, Prentice Hall, 1978, pp 1-242.
9. Farber E: Ethionine carcinogenesis. Adv Cancer Res 1963;7:383-474.
10. Farber E, Cameron R: The sequential analysis of liver cancer induction. Adv Cancer Res 1979;31:125-226.
11. Farr RSA: Quantitative Immunochemical measure of the primary interaction between I * BSA and antibody. J Infect Dis 1958;103:237-262.
12. Yalow RS, Berson SA: Immunoassay of endogenous insulin in man. J Clin Invest 1960;39:1157-1175.
13. Sell S: Radioimmunoassay of rat α1-fetoprotein. Cancer Res 1973;33:1010-1015.
14. Gitlin D, Boesman M: Sites of α-fetoprotein synthesis in the human and in the rat. J Clin Invest 1967;46:1010-1016.
15. Sell S, Jalowayski I, Bellone C, Wepsic HT: Isolation and characterization of rat α1-fetoprotein. Cancer Res 1972;32:1184-1189.
16. Ruoslahti D, Seppala M: Studies on carcinofetal proteins III: development of a radioimmunoassay for α-fetoprotein - demonstration of α-fetoprotein in healthy human adults. Int J Cancer 1971;8:374-383.
17. Purves LR, Purves M: Serum AFP VI: the radioimmunoassay evidence for the presence of AFP in the serum of normal people and during pregnancy. S Afr Med J 1972;46:1290-1298.
18. Oakes DD, Shuster J, Gold P: Radioimmunoassay for α1-fetoprotein in the serum of rats. Cancer Res 1972;32:2753-2760.
19. Hirai H, Nishi S, Watabe H: Radioimmunoassay for α-fetoprotein; in Peeters H (ed): Protides of the Biological Fluids. Oxford, Pergamon Press, 1973, pp 579-587.
20. Sell S, Gord D: Refinement of radioimmunoassay for detection of 1 ng rat α-1 fetoprotein. Immunochemistry 1973;10:439-442.
21. Sell S, Becker FF: α-Fetoprotein. J Natl Cancer Inst 1978;60:19-26.
22. Sell S, Skelly H: Tissue sites of α1-fetorpotein synthesis by the rat during pregnancy and hepatoma growth. J Natl Cancer Inst 1976;56:645-648.
23. Sala-Trepat JM, Dever J, Sargent TD, Thomas K, Sell S, Bonner J: Changes in expression of albumin and α-fetoprotein genes during rat liver development and neoplasia. Biochemistry 1979;18:2167-2178.
24. Sell S, Alexander D: Rat α-1-fetoprotein. V. Catabolism and fetal-maternal distribution. J Nat Cancer Inst 1974;52:1483-1489.
25. Sell S, Sala-Trepat J, Sargent T, Thomas K, Nahon J-L, Goodman T, Bonner J: Molecular mechanisms of control of albumin and α-fetoprotein production: a system to study the early effects of chemical hepatocarcinogens. Cell Biol Int Rep 1980;4:235-254.
26. Sell S, Nichols M, Becker FF, Leffert JL: Hepatocyte proliferation and α1-fetoprotein in pregnant, neonatal and partially hepatectomized rats. Cancer Res 1974;34:865-871.
27. Mizejewski GJ: α-Fetoprotein structure and function: relevance to isofoms, epitopes, and conformational variants. Exp Biol Med 2001;226:377-408.
28. Mizejewski GJ: Biological roles of α-fetoprotein during pregnancy and perinatal development. Exp Biol Med 2004;229:439-463.
29. Parmely MJ, Thompson JS: Inhibition of rat lymphocyte cultures by serum fractions rich in α-fetoprotein; in Masseyeff R (ed): α-Fetoprotein. Paris, Inserm, 1974, p 467.
30. Murgita RA, Tomasi TB: Suppression of the immune response by α-fetoprotein. I the effect of mouse α-fetoprotein on the primary and secondary antibody response. J Exp Med 1975;141:269-286.
31. Murgita RA, Tomasi TB: Suppression of the immune response by α-fetoprotein II. The effect of mouse α-fetoprotein on mixed lymphocyte reactivity and mitogen induced lymphocyte transformation. J Exp Med 1975;141:440-452.
32. Uriel J, Trojan J, Moro R, Pineiro A: Intracellular uptake of α-fetoprotein: a marker of neuronal differentiation. Ann NY Acad Sci 1983;417:321-329.
33. Gabant P, Forrester L, Nichols J, Van Reeth T, De Mees C, Pajack B, Watt A, Smitz J, Alexandre H, Szpirer C, Szpirer J: α-Fetoprotein, the major fetal serum protein, is not essential for embryonic development but is required for female fertility. Proc Natl Acad Sci USA 2002;99:12865-12890.
34. DeMees C, Laes J-F, Bakker J, Smitz J, Hennuy B, Van Vorren P, Gabant P, Szpierer J, Szpirer C: α-Fetoportein controls female fertility and prenatal development of the gonadotropin-releasing hormone pathway through an antiestrogenic action. Mol Cell Biol 2006;26:2012-2018.
35. Bakker J, DeMees C, Souhard Q, Balthazart J, Gabant P, Szpirer J, Szpirer C: α-Fetoprotein protects the developing female mouse brain from masculinization and defeminization by estrogens. Nat Neurosci 2006;9:220-226.
36. Sheppard HW, Sell S, Threfts P, Bahu R: Effects of α-fetoprotein on murine immune responses. I. Studies on mice. J Immunol 1977;119:91-97.
37. Sheppard HW, Sell S, Threfts P, Bahu R: Effects of α-fetoprotein on murine immune responses. II. Studies on rats. J Immunol 1977;119:98-103.
38. Attardi B, Ruoslathi E: Foetoneonatal oestradiol-binding protein in mouse brain cytosol is α-foetoprotein. Nature 1976;263:685-687.
39. Benno RW, Williams TH: Evidence for intracellular localization of α-fetoprotein in the developing rat brain. Brain Res 1978;142:182-186.
40. Trojan J, Uriel J: Intracellullar localization of α-fetoprotein and serum albumin in the central nervous system of the developing rat. CR Seances Acad Sci 1979;289:1157-1160.
41. Sell S, Longley MA, Boulter J: α-Fetoprotein and albumin gene expression in brain and other tissues of fetal and adult rats. Brain Res 1985;354:49-53.
42. Higgins GM, Anderson RM: Experimental pathology of the liver: restoration of the liver of the white rat following partial surgical removal. AMA Arch Pathol 1991;139:1352-1368.
43. Steiner JW, Pera ZM, Taichman LB: Cell population dynamics in the liver: a review of quantitative morphological techniques applies to the study of physiological and pathological growth. Exp Mol Pathol 1966;5:146-181.
44. Sell S, Nichols M, Becker FF, Leffert JL: Hepatocyte proliferation and α1-fetoprotein in pregnant, neonatal and partially hepatectomized rets. Cancer Res 1974;34:865-871.
45. Sell S: Heterogeneity of α-fetoprotein (AFP) and albumin containing cells in normal and pathological permissive states for AFP production: AFP containing cells induced in adult rats recapitulate the appearance of AFP containing hepatocytes in fetal rats. Oncodev Biol Med 1980;1:93-105.
46. Engelhardt NV, Lazareva MN, Abelev GI, Uryaeva IV, Factor VM, Brodsky VY: Detection of α-fetoprotein in mouse liver differentiated hepatocytes before their progression through S phase. Nature 1976;263:146-148.
47. Sell S: The role of liver progenitor cells in repair of liver injury and in liver transplantation. Wound Repair Regen 2001;9:467-482.
48. Sell S: Heterogeneity and plasticity of hepatocyte lineage cells. Hepatol 2001;33:738-750.
49. Sell S: Comparison of liver progenitor cells in human atypical ductular reactions with those seen in experimental models of liver injury. Hepatology 1998;27:317-331.
50. Grisham JW, Porta EA: Origin and fate of proliferated hepatic ductal cells in the rat: electron microscopic and autoradiographic studies. Exp Mol Pathol 1964;3:242-261.
51. Ruben E: The origin and fate of proliferated bile ductular cells. Exp Mol Pathol 1964;3:279-286.
52. Sell S, Reynolds RD, Reutter WJ: Rat α1-fetoprotein: appearance after galactosamine-induced liver injury. J Natl Cancer Inst 1974;53:289-291.
53. Tournier I, Legres L, Schoevaert D, Feldman G, Bernuau D: Cellular ahalysis of α-fetoprotein gene acitivation during carbon tetrachloride and D-galactosamine-induced acute liver injury in rats. Lab Invest 1998;59:657-665.
54. Petersen BE, Zajec AF, Michalopoulos GK: Hepatic oval cell activation in response to injury following chemically induced periportal of pericentral damage in rats. Hepatology 1998;27:1030-1038.
55. Yin L, Lynch D, Ilic Z, Sell S: Proliferation and differentiation of ductular liver precursor cells and non-parenchymal cells during the restitutive response of the rat liver to carbon tetrachloride injury after inhibition of hepatocyte proliferation by n-2-acetylaminofluorine. Histol Histopathol 2002;17:65-81.
56. Lopez M, Mazzanti L: Experimental investigation of alpha- naphthylisothiocyanate as a hyperplastic agent of the biliary ducts in the rat. J Pathol Bacteriol 1955;69:243-250.
57. Sell S: Comparison of oval cells induced in rat liver by feeding N-2-fluorenylacetamide in a choline devoid diet and bile ducts induced by feeding 4,4-diaminodiphenylmethane. Cancer Res 1983;43:1761-1767.
58. Best DH, Coleman WB: Bile duct destruction by 4,4′- diaminodiphenylmethane does not block the small hepatocyte-like progenitor cell response in retrorsine-exposed rats. Hepatology 2007;46:1611-1619.
59. Yavorkovsky L, Lai E, Ilic Z, Sell S: Participation of small intra-portal stem cells in the restitutive response to periportal injury induced by allyl alcohol. Hepatology 1995;21:1702-1712.
60. Sell S: Electron microscopic identification of putative liver stem cells and intermediate hepatocytes following periportal necrosis induced in rats by allyl alcohol. Stem Cells 1997;15:378-385.
61. Yin L, Lynch D, Sell S: Participation of different cell types in the restitutive response of the rat liver to periportal injury induced by allyl alcohol. J Hepatol 1999;31:492-507.
62. Rosenberg D, Ilic Z, Sell S: Proliferation of hepatic lineage cells of normal C57BL and IL-6 knockout mice after cocaine-induced periportal injury. Hepatology 2000;31:948-955.
63. Sell S: Adult stem cell plasticity. Stem Cell Rev 2005;1:1-8.
64. Thorgeirsson SS, Grisham JW: Hematopoietic cells as hepatocyte stem cells: a critical review of the evidence. Hepatology 2006;43:2-8.
65. Grompe M, al-Dhalimy M, Finegold M, et al: Loss of fumarylacetoacetate hydrolase is responsible for the neonatal hepatic dysfunction phenotype of lethal albino mice. Genes Dev 1993;7:2298-2307.
66. Lagasse E, Connors H, Al-Dhalimy M, et al: Purified hematopoietic stem cells can differentiate into hepatocytes in vivo. Nat Med 2000;6:1229-1234.
67. Vassilopoulos G, Wang PR, Russell DW: Transplanted bone marrow regenerates liver by cell fusion. Nature 2003;422:901-904.
68. Wang X, Willenbring H, Akkari Y, Torimaru Y, Foster M, Al-Dhalimy M, Lagasse E, Finegold M, Olson S, Grompe M: Cell fusion is the principal source of bone-marrow-derived hepatocytes. Nature 2003;422:897-901.
69. Vig P, Russo FP, Edwards RJ, Tadrous PJ, Wright NA, Thomas HC, Alison MR, Forbes SJ: The sources of parenchymal regeneration after chronic hepatocellular liver injury in mice. Hepatology 2006;43:316-324.
70. Petersen BE, Bowen WC, Patrene KD, et al: Bone marrow as a potential source of hepatic oval cells. Science 1999;284:1168-1170.
71. Oh SH, Witek RP, Bae SH, et al: Bone marrow-derived hepatic oval cells differentiate into hepatocytes in 2-acetylaminofluorene/partial hepatectomy-induced liver regeneration. Gastroenterology 2007;132:1077-1087.
72. Menthena A, Deb N, Oertel M, et al: Bone marrow progenitors are not the source of expanding oval cells in injured liver. Stem Cells 2004;22:1049-1061.
73. Moritoki Y, Ueno Y, Kanno N, et al: Lack of evidence that bone marrow cells contribute to cholangiocytic repopulation during experimental cholestatic ductal hyperplasia. Liver Int 2006;26:457-466.
74. Wulf GG, Luo K-L, Jackson KA, Brenner MK, Goodell MA: Cells of the hepatic side population contribute to liver regeneration and can be replenished by bone marrow stem cells. J Hematol 2003;88:368-378.
75. Rountree CB, Barsky L, Ge S, Senadheera S, Crooks GM: A CD133 expressing murine liver oval cell population with bi-lineage potential. Stem Cells 2007;25:2419-2429.
76. Roundtree CB, Wang X, Ge S, Barsky L, Zhu J, Gonzales I, Crooks GM: Bone marrow fails to differentiate into liver epithelium during murine development and regeneration. Hepatology 2007;45:1250-1260.
77. Ochsner SA, Strick-Marchand H, Qiu Q, Venable S, Dean A, Wilde M, Weiss MC, Darlington GJ: Transcriptional profiling of bipotential embryonic liver cells to identify liver progenitor cell surface markers. Stem Cells 2007;25:2476-2487.
78. Swenson ES, Guest I, Ilic Z, Mazzeo M, Lizardi P, Hardiman C, Sell S, Krause DS: Hepatocyte nuclear factor-1 as a marker of epithelial phenotype reveals marrow-derived hep atocytes, but not duct cells, after liver injury in mice. Stem Cells 2008; PMID: 18467658.
79. Morris HP, Wagner BP: Induction and transplantation of rat hepatomas with different growth rate (including 'minimal deviation' hepatomas); in Busch H (ed): Methods in Cancer Research. New York, Academic Press, 1968, pp 125-152.
80. Sell S, Morris HP: Relationship of rat α1-fetoprotein to growth rate and chromosome composition of Morris hepatomas. Cancer Res 1974;34:1413-1417.
81. Sell S, Wepsic HT, Nickel R, Nichols M: Rat α1-fetoprotein IV: the effect of growth and surgical removal of Morris hepatoma 7777 upon the serum α1-fetoprotein concentrations of Buffalo rats. J Natl Cancer Inst 1974;52:133-137.
82. Sell S, Stillman D, Michaelsen M, Alaimo J, VonEssen C: Prevention of pulmonary metastases by irradiation of the lung: a model system employing a transplantable hepatoma and α1-fetoprotein as an index of tumor growth. Radiat Res 1977;69:54-64.
83. Reya T, Morrison SJ, Clarke MF, Weissman IL: Stem cells, cancer, and cancer stem cells. Nature 2001;414:105-111.
84. Wicha MS, Liu S, Dontu G: Cancer stem cells: an old idea - a paradigm shift. Cancer Res 2006;66:1883-1890.
85. Van Wijk T: Regulation of DNA synthesis in cultured rat hepatoma cells. Int Rev Cytol 1983;85:63-107.
86. Looney WB, Mayo AA, Janners MY, et al: Cell proliferation and tumor growth in hepatoma 3924A. Cancer Res 1971;31:821-825.
87. Morris HP, Meranze DR: Induction and some characteristics of 'minimal deviation' and other transplantable rat hepatomas. Recent Results Cancer Res 1974;44:103-111.
88. Kovacs CJ, Evans MJ, Wakefield JA, Looney WB: A comparative study of the response to radiation by experimental tumors with markedly different growth characteristics. Radiat Res 1977;72:455-468.
89. Potter VR: Recent trends in cancer biochemistry: the importance of studies on fetal tissue. Proc Can Cancer Conf 1969;8:9-30.
90. Potter VR: Phenotypic diversity in experimental hepatomas;the concept of partially blocked ontogeny. Br J Cancer 1978;38:1-23.
91. Potter VR: The present status of the blocked ontogeny hypothesis of neoplasia: the Thalassemia connection. Oncodev Biol Med 1981;2:243-266.
92. Ono T: Enzyme patterns and malignancy of experimental hepatomas. Gann Monogr Cancer Res 1966;1:189-206.
93. Sugimura T, Matsushima T, Kawachi T, Hirata Y, Kawabe S: Molecular species of aldolases and hexokinases in experimental hepatomas. Gann Monogr Cancer Res 1966;1:143-150.
94. Schapira F: Aldolase isozymes in cancer. Eur J Cancer 1966;2:131-134.
95. Matsushima T, Kawabe S, Shibuya M, Sugimura T: Aldolase isozyme in rat tumor cells. Biochem Biophys Res Commun 1968;30:565-570.
96. Farber E: On the concept of minimal deviation in the study of the biochemistry of cancer. Cancer Res 1968;28:1210-1211.
97. Sell S: Diagnostic applications of α-fetoprotein: government regulations prevent full application of a clinically useful test. Hum Pathol 1981;12:959-963.
98. Sell S: Stem cells in hepatocarcinogenesis. Cell Sci Rev 2006;3:302-341.
99. Yoshida T: o-Aminoazotoluol: Über die experimentelle annulare Lebercirrhose des Kaninchens. Trans Jpn Pathol Soc 1935;25:409-411.
100. Kinosita R: Special report: studies on the cancerogenic chemical substances. Trans Jpn Pathol Soc 1937;27:655-725.
101. Orr JW: The histology of the rat's liver during the course of carcinogenesis by butter-yellow (p-dimethylaminoazobenzene). J Pathol Bacteriol 1940;50:393-408.
102. Opie EL: The pathogenesis of tumors of the liver produced by butter yellow. J Exp Med 1944;80:231-246.
103. Farber E: Similarities in the sequence of early histologic changes induced in the liver by ethionine, 2-acetylaminofluorene, and 3′-methyl-4-dimethylamionazobenzene. Cancer Res 1956;16:142-148.
104. Farber E, Sarma DSR: Hepatocarcinogenesis: a dynamic cellular perspective. Lab Invest 1987;56:4-22.
105. Pitot HC: The natural history of neoplastic development: the relation of experimental models to liver cancer. Cancer 1982;49:1206-1211.
106. Scherer E: Neoplastic progression in experimental hepatocarcinogenesis. Biochim Biophys Acta 1984;738:219-236.
107. Rabes HM: Development and growth of early preneoplastic lesions induced in the liver by chemical carcinogens. J Cancer Res Clin Oncol 1983;106:85-91.
108. Bannasch P: Sequential cellular changes during chemical carcinogenesis. J Cancer Res Clin Oncol 1984;108:11-22.
109. Bannasch P, Hacker HJ, Klinek F, Mayer D: Hepatocellular glycogenosis and related pattern of enzymatic changes during hepatocarcinogenesis. Adv Enzyme Regul 1984;22:97-121.
110. Aterman KJ: The stem cells of the liver - a selective review. Cancer Clin Oncol 1992;118:87-115.
111. Becker FF, Sell S: Differences in serum α-fetoprotein concentrations during the carcinogenic sequences resulting from exposure to diethylnitrosamine or acetylaminofluorene. Cancer Res 1979;39:1437-1442.
112. Teebor GW, Becker FF: Regression and persistence of hyperplastic hepatic nodules induced by N-2-fluorenylacetamide and their relationship to hepatocarcinogenesis. Cancer Res 1971;31:1-3.
113. Sell S: Distribution of α-fetoprotein and albumin containing cells in the livers of Fisher rats fed four cycles of N-2-fluorenylacetamide. Cancer Res 1978;75:181-186.
114. Sell S, Leffert HL: An evaluation of cellular lineages in the pathogenesis of experimental hepatocellular carcinoma. Hepatology 1982;2:77-86.
115. Shinozuka H, Lombardi B, Sell S, Iammarino RM: Modification of ethionine liver carcinogenesis by choline deficiency: early histological and functional alterations. Cancer Res 1978;38:1092-1098.
116. Shinozuka H, Lombardi B, Sell S, Iammarino RM: Enhancement of DL-ethionine-induced liver carcinogenesis in rats fed a choline devoid diet. J Natl Cancer Inst 1978;61:813-818.
117. Sell S, Osborn K, Leffert HL: Autoradiography of 'oval cells' appearing early in the livers of rats fed N-2-fluorenylacetamide in choline devoid diet. Carcinogenesis 1981;2:7-14.
118. Sell S, Salman J: Light and electronmicroscopic autoradiographic analysis of proliferating cells during the early stages of chemical hepatocarcinogenesis in the rat induced by feeding N-2-fluorenylacetamide in a choline deficient diet. Am J Pathol 1984;114:287-300.
119. Solt DB, Farber E: New principle for the analysis of chemical carcinogenesis. Nature 1976;263:702-703.
120. Sell S, Dunsford H: Evidence for the stem cell origin of hepatocellular carcinoma and cholangiocarcinoma. Am J Pathol 1989;134:1347-1363.
121. Dunsford A, Maset R, Salman J, Sell S: Connection of ductlike structures induced by a chemical hepatocarcinogen to portal bile ducts in the rat liver detected by injection of bile ducts with a pigmented barium gelatin medium. Am J Pathol 1985;118:218-224.
122. Sell S: The role of determined stem-cells in the cellular lineage of hepatocellular carcinoma. Int J Dev Biol 1993;33:189-201.
123. Schmidt D, Harms D, Lang W: Primary hepatic tumours in childhood. Virchows Arch A Pathol Anat Histopathol 1985;407:387-405.
124. Kasai M, Watanabe I: Histologic classification of liver cell carcinoma in infancy and childhood and its clinical evaluation. Cancer 1970;25:551-563.
125. Haas R, Muczynski KA, Krailo M, et al: Histopathology and prognosis in childhood hepatoblastona and hepatocarcinoma. Cancer 1989;64:1082-1095.
126. Sell S, Pierce GB: Maturation arrest of stem cell differentiation is a common pathway for the cellular origin of teratocarcinomas and epithelial cancers. Lab Invest 1994;70:6-21.
127. Moro R, Tanaoki T, Wegmann TG, Longnecker BM, Laderoute MP: Monoclonal antibodies directed against a sidespread oncofetal antigen: the α-fetoprotein receptor. Tumour Biol 1993;14:116-130.
128. Sonnenschein C, Soto AM: Growth inhibition of estrogen-sensitive tumor cells in newborn rats: probable role of α-fetoprotein. J Natl Cancer Inst 1979;63:835-841.
129. Sonnenschein D, Ucci A, Soto AM: Growth inhibition of estrogen-sensitive rat mammary tumors: effect of an α-fetoprotein-secreting hepatoma. J Natl Cancer Inst 1980;64:1147-1152.
130. Bennett JA, Mesfin FB, Andersen TT, Gierthy JF, Jacobson HI: A peptide derived from α-fetoprotein prevents the growth of estrogen-dependent human breast cancers sensitive and resistant to tamoxifen. Proc Natl Acad Sci 2002;99:2211-2215.
131. Recamier JCA: Recherches sur le traitement du cancer: par la compression methodique simple ou combinee, et sur l'histoire general de la meme maladie. Paris, Gabon, 1829.
132. Remark R: Ein Beitrag zur Entwickelungsgeschichte der krebshaften Geschwulste. Dtsch Klin 1854;6:70-174.
133. Virchow R: Die krankhaften Geschwülste. Berlin, Hirschwald, 1863.
134. Durante F: Nesso fisio-pathologico tra la struttura dei nei materni e la genesi di alcuni tumori maligni. Arch Memor Osserv Chir Pract 1874;11:217-226.
135. Cohnheim J: Congenitales, quergestreiftes Muskelsarkom der Nieren. Virchows Arch 1875;65:64.
136. Bainbridge WS: The Cancer Problem. New York, Macmillan, 1914.
137. Peyron A: Sur la présence des cellules génitales primordiales dans les boutons embryonnaires des embryones parthenogé nétiques chez l'homme. CR Acad Sci (Paris) 1938;206:1680-1683.
138. Braunstein GD, McIntire KR, Waldmann TA: Discordance of human chorionic gonadotropin and α-fetoprotein in testicular teratocarcinomas. Cancer 1973;31:1065-1068.
139. Willemse PHB, Sleijfer DT, Schraffordt Koops H, De Bruijn HWA, Oosterhuis JW, Brouwers TM, Ockhuizen T, Marrink J: Tumor markers in patients with non-seminomatous germ cell tumors of the testis. Oncodev Biol Med 1981;2:117-128.
140. Vogelzang NJ, Lange PH, Goldman A, Vessela RH, Fraley EE, Kennedy BJ: Acute changes of α-fetoprotein and human chorionic gonadotropin during induction chemotherapy of gem cell tumors. Cancer Res 1982;42:4855-4861.
141. Stevens LE, Little CC: Spontaneous testicular teratomas in inbred strains of mice. Proc Natl Acad Sci USA 1954;40:1080-1087.
142. Stevens LC: Origin of testicular teratomas from primordial germ cells in mice. J Natl Cancer Inst 1967;38:549-552.
143. Stevens LC: Experimental production of testicular teratomas in mice. Proc Natl Acad Sci USA 1964;52:654-661.
144. Rippert V: Das Carcinoma des Menschen, Geschwulstlehre. Bonn, 1911.
145. Damjanov I, Skreb N, Sell S: Origin of embryo-derived yolk sac carcinomas. Int J Cancer 1977;19:526-530.
146. Pierce GB, Dixon FL, Varney EL: Teratocarcinogenic and tissue forming potentials of the cell types comprising neoplastic embryoid bodies. Lab Invest 1960;9:583-602.
147. Pierce GB, Wallace C: Differentiation of malignant cells to benign cells. Cancer Res 1971;31:127-124.
148. Brinster RL: Effect of cells transferred into the mouse blastocyst on subsequent development. J Exp Med 1974;140:1049-1056.
149. Mintz B, Illmensee K: Normal genetically mosaic mice produced from malignant teratocarcinoma cells. Proc Natl Acad Sci USA 1975;72:3583-3589.
150. Papaioannou VE, McBurndy MW, Gardner RL, Evans MJ: Fate of teratocarcinoma cells injected into early mouse embryos. Nature 1975;258:70-73.
151. Pierce GB, Arechaga J, Jones A, Lewellyn A, Wells RS: The fate of embryonal-carcinoma cells in mouse blastocysts. Differentiation 1987;33:247-253.
152. Pierce GB, Spears WC: Tumors as caricatures of the process of tissue renewal: prospects for therapy by directing differentiation. Cancer Res 1988;48:1196-1204.
153. Yoshitake T, Itoyama S: Treatment of primary mediastinal germ cell tumors. Tinsho Kyobu Geka 1989;9:29-34.
154. Sell S: Stem cell origin of cancer and differentiation therapy. Crit Rev Oncol Hematol 2004;51:1-28.
155. Sell S: Potential gene therapy strategies for cancer stem cells. Curr Gene Ther 2006;6:579-591.
156. Sell S: Cancer and stem cell signaling: a guide to preventive and therapeutic strategies for cancer stem cells. Stem Cell Rev 2007;3:1-6.
157. Sell S: Leukemia: stem cells, maturation arrest, and differentiation therapy. Stem Cell Rev 2005;1:197-205.
158. Sell S: Cancer stem cells and differentiation therapy. Tumor Biol 2006;27:59-70.
159. Drucker BJ, Guilhot F, O'Brian SG, et al: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-2417.
160. Segalla S, Rinaldi L, Kilstrup-Nielsen C, Badaracco G, et al: Retinoic acid receptor α fusion to PML affects in transcriptional and chromatin-remodeling properties. Mol Cell Biol 2003;23:8795-8808.
161. Pitha-Rowe I, Petty WJ, Kitareewan S, Dmitrovsky E: Retinoid target genes in acute promyelocytic leukemia. Leukemia 2003;17:1723-1730.
162. Chalandon Y, Schwaller J: Targeting mutated protein tyrosine kinases and their signaling pathways in hematologic malignancies. Haematologica 2005;90:949-968.
163. Gilliand DG, Griffin JD: The role of FLT3 in hematopoiesis and leukemia. Blood 2002;100:1332-1342.
164. Feldman EJ: Faresyltransferase inhibitors in melodysplastic syndrome. Curr Hematol Rep 2004;4:186-190.
165. Puck TT, Marcus PI: A rapid method of viable cell titration and clone production with HeLa cells in tissue culture: use of xirradiated cells to supply conditioning factors. Proc Natl Acad Sci USA 1955;41:432-437.
166. Buick RN: In vitro clonogenicty of primary human tumor cells: quantitation and relationship to tumor stem cells; in Salmon S (ed): Cloning of Humor Tumor Stem Cells. New York, AR Liss, 1980, pp 15-20.
167. Salmon S: In vitro effects of drugs on human tumor stem cell assays; in Salmon S (ed): Cloning of Human Tumor Stem Cells. New York, AR Liss, 1980, pp 197-312.
168. Greene HSN: The significance of the heterologous translatability of human cancer. Cancer 1952;5:24-44.
169. Reinhard MC, Goltz HL, Warner SC: Further studies on the quantitative determination of the growth of a transplantable mouse adenocarcinoma. Cancer Res 1952;5:102-106.
170. Hewitt HB: Transplantation of mouse sarcomas with small numbers of single cells. Nature 1952;170:622-623.
171. Lapidot T, Sirard C, Bormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, Dick JE: A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994;367:645-648.
172. Bonnet D, Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730-737.
173. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MR: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003;100:3983-3988.
174. Lee J-S, Heo J, Libbrecht L, Chu I-N, Kaposi-Novak P, Calvisi, DF, Mikaelyan A, Roberts LR, Demetris AJ, Sun A, Nevens F, Roskams T, Thorgeirsson SS: A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 2006;12:410-416.
175. Yin S, Li J, Hu C, Chen X, Yao M, Yan M, Jiang G, Ce C, Xie H, Wan D, Yang S, Zheng S, Gu J: CD133 positive hematocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer 2007;120:1444-1450.
176. Ma S, Chan KW, Hu L, Lee TK, Wo JY, Ng IO, Zheng BJ, Guan XY: Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 2007;132:2542-2556.
177. Ma S, Lee, TK, Zheng B-J, Chan KW, Guan X-Y: CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 2008;27:1749-1758.
178. Yang ZF, Ngai P, Ho DW, Yu WC, Ng MNP, Lau CK, Li MLY, Tam KO, Lam CT, Poon RTP, Fan ST: Identification of local and circulating cancer stem cells in human liver cancer. Hepatology 2008;47:919-928.
179. Yang ZF, Ho DW Ng MN, Lau CK, Yu WC, Ngal P, Chu PEK, Lan CT, Poon RTP, Fan ST: Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 2008;13:153-166.
180. Zen Y, Fujii T, Yoshikawa S, Takamura H, Tani T, Ohtia T, Nakanuma Y: Histological and culture studies with respect to ABCG2 expression support the existence of a cancer cell hierarchy in human hepatocellular carcinoma. Am J Pathol 2007;170:1750-1762.
181. Yamashita T, Forgues M, Wang W, Kim JW, Ye Q, Jia H, Budu A, Zanetti KA, Chen Y, Qin L-X, Tang Z-Y, Wang XW: EpCAM and α-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res 2008;68:1451-1461.
182. Kaposi-Novak P, Lee J-S, Gomez-Quiroz L, Coulouarn C, Factor VM, Thorgeirsson SS: Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest 2006;116:1582-1595.
183. Trott KR: Tumour stem cells: the biological concept and its application in cancer treatment. Radiother Oncol 1994;30:1-5.
184. Denekamp J: Tumour stem cells: facts, interpretation and consequences. Radiother Oncol 1994;30:6010.
185. Rich JN: Cancer stem cells in radiation resistance. Cancer Res 2007;67:8980-8984.
186. Cairns J: Somatic stem cells and the kinetics of mutagenesis and carcinogenesis. Proc Natl Acad Sci USA 2002;99:10567-10570.
187. Cairns J: Cancer and the immortal strand hypothesis. Genetics 2006;174:1069-1072.
188. Sell S: Cancer and stem cell signaling: a guide to preventive and therapeutic strategies for cancer stem cells. Stem Cell Rev 2007;3:1-6.